In peptide research, the combination of TB-500 (Thymosin Beta-4 Fragment) and BPC-157 (Body Protection Compound-157) is considered particularly interesting. Both peptides address tissue regeneration through different mechanisms — a property termed synergism in pharmacology.
Synergism means the combined effect of two substances exceeds the sum of their individual effects. This is distinct from an additive effect.- 💡 Note
TB-500 acts through actin binding and modulation of actin polymerisation. It promotes the mobilisation of stem cells from bone marrow and their migration to injured tissues. Its systemic mode of action means TB-500 is active throughout the organism regardless of the site of application.
BPC-157 acts via the NO system (nitric oxide) and stimulates VEGF-dependent angiogenesis. Unlike TB-500, BPC-157 shows particular activity in mucous membranes, the gastrointestinal tract and tendon tissue. It also modulates dopaminergic and serotonergic systems.
Direct combination studies on TB-500 and BPC-157 are not yet available in the literature to any substantial degree. The rationale for the combination arises from the complementary targets: TB-500 operates primarily via actin signalling pathways, BPC-157 via the NO/VEGF system. Both activate angiogenesis, but through different receptor systems.
All data on BPC-157 and TB-500 derive from preclinical studies (animal and cell models). Human studies are currently absent. Studien Peptide provides these compounds exclusively for scientific research purposes.- ⚗️ Research note
What do we know in 2026 about the lipolytic mechanisms of HGH Fragment 176-191 (AOD9604)? Current research data on beta-3-AR and fat breakdown.
GHK-Cu (copper peptide) modulates over 4,000 genes. New research findings on wound healing, collagen synthesis and epigenetic effects.
GHK-Cu (Glycyl-L-Histidyl-L-Lysine-Copper) is an endogenous tripeptide with extraordinary biological activity on collagen and DNA repair.